BERLIN--(BUSINESS WIRE)-- Bayer today announced results from the ongoing global Phase I first-in-human, dose-escalation PAnTHa study (NCT06217822) evaluating the safety, tolerability and preliminary ...
A new targeted alpha therapy is showing promise for patients whose thyroid cancer no longer responds to radioactive iodine, the standard beta-emitting treatment. In a first-in-human study, ...
One of the highest-risk components of nuclear waste is iodine-129 (I-129), which stays radioactive for millions of years and accumulates in human thyroids when ingested. In the U.S., nuclear waste ...
JAKARTA, Oct 3 (Reuters) - Indonesia has detected radioactive contamination at a sprawling industrial zone near the capital Jakarta, found to have high levels of Caesium-137 (Cs-137), a manmade ...
For the second time in a week, a company is recalling shrimp imported from Indonesia due to potential contamination with radioactive material. California-based Southwind Foods announced Aug. 21 that ...
Comparative analysis of stereotactic body radiotherapy (SBRT) vs. SBRT with bridge therapies for hepatocellular carcinoma patients awaiting liver transplantation: A multi-center study (2010-2020).
A secondary analysis of the phase III VISION trial presented at this year's American Society of Clinical Oncology (ASCO) Genitourinary Cancers Symposium found that adding androgen receptor pathway ...
Comparing quality of life in prostate cancer patients: Continuous vs. intermittent androgen deprivation therapy—A systematic review and meta-analysis. This is an ASCO Meeting Abstract from the 2025 ...
Ariceum Therapeutics (Ariceum), a private biotech company developing radiopharmaceutical products for the diagnosis and treatment of certain hard-to-treat cancers, today announced that the U.S. Food ...
AdvanCell has secured $112 million in a Sanofi Ventures-backed series C funding round as the Australian radiopharma company takes its lead candidate through a prostate cancer trial. The Pb-212-based ...
Richland, WA, Dec. 23, 2024 (GLOBE NEWSWIRE) -- – Vivos Inc. (OTCQB: RDGL) proudly announces the initiation of its first human clinical trial for RadioGel ® Precision Radionuclide Therapy™ in India.
WEST CHESTER, Pa.--(BUSINESS WIRE)--Molecular Targeting Technologies, Inc. (MTTI), is delighted to be working with Brookline Capital Markets at the 2nd Targeted Radionuclide Pharmaceuticals (TRPs) ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results